First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future

“…However, in another phase II trial (DOCETUX), the addition of cetuximab to chemotherapy as a first-line treatment improved the overall response rate (ORR) but did not prolong the TTP and OS. The same results were obtained by Quintero Aldana et al [23] in their phase II trial. In esophageal squamous cell carcinoma patients, cetuximab was tested in a phase II trial [24], whereas panitumumab was studied in a phase III trial [25]: both groups had no improvement of outcomes adding cetuximab/panitumumab to first-line chemotherapy.…”

“…The best known and most successful classes of drugs to date are anti-EGFRs and antiangiogenics 10–15,20–29. These drugs are safe, used and approved for various types of cancer.…”

“…The same results were obtained by Quintero Aldana et al . [23] in their phase II trial. In esophageal squamous cell carcinoma patients, cetuximab was tested in a phase II trial [24], whereas panitumumab was studied in a phase III trial [25]: both groups had no improvement of outcomes adding cetuximab/panitumumab to first-line chemotherapy.…”

Research progress in targeted therapy and immunotherapy for gastric cancer

“…A study assessed the efficacy and safety of panitumumab plus first-line chemotherapy (docetaxel and cisplatin) in treating patients with advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma. However, this study showed that adding panitumumab to standard chemotherapy as the first-line treatment did not improve the efficacy outcomes [20] …”

“…However, this study showed that adding panitumumab to standard chemotherapy as the first-line treatment did not improve the efficacy outcomes. [ 20 ]…”